Want to see ASMB full AI Analyst Report?
ASMB Stock Chart & Stats
$35.33
$0.60(2.35%)
At close: 4:00 PM EDT
$35.33
$0.60(2.35%)
Day’s Range― - ―
52-Week Range$19.94 - $39.71
Previous CloseN/A
Volume1.34K
Average Volume (3M)336.73K
Market Cap
$410.47M
Enterprise Value$200.09M
Total Cash (Recent Filing)$320.36M
Total Debt (Recent Filing)$2.35M
Price to Earnings (P/E)36.5
Beta1.43
Next Earnings
Nov 11, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.55
Shares Outstanding20,360,596
10 Day Avg. Volume236,768
30 Day Avg. Volume336,728
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit3.44
Enterprise Value/Ebitda2.94K
Forecast
1Y Price Target
$49.50Price Target Upside40.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.15
Revenue Forecast (FY)$52.01M
Bulls Say, Bears Say
Bulls Say
Revenue ScalingRevenue has scaled substantially from prior years, indicating meaningful commercial or development-related progress in the business. If this higher revenue base persists, it can support broader investment in the pipeline and improve operating leverage as the company advances its programs.
Strong Gross MarginA gross margin near 78% provides a strong economic foundation relative to the company’s current revenue base. Maintaining this level would allow more revenue to fund research and development, support future commercialization efforts, and improve the potential for eventual operating profitability.
Low Financial LeverageMinimal debt reduces interest and refinancing pressure while preserving financial flexibility for a clinical-stage company. The substantial equity base gives Assembly Biosciences greater capacity to fund operations and advance development programs without relying heavily on debt financing.
Bears Say
Persistent Cash BurnMaterially negative operating and free cash flow shows that the business is not yet self-funding its operations. Continued cash burn can require additional financing or use of existing resources, potentially limiting development flexibility and increasing funding pressure over the next several quarters.
Negative Operating ProfitabilityNear-breakeven net income has not yet translated into positive operating profitability, leaving the core business economically unproven. Negative EBIT and EBITDA constrain internally generated funding and make sustainable earnings dependent on further revenue growth or cost improvements.
Clinical-Stage Execution RiskAssembly Biosciences remains focused on research, clinical trials, and advancing proprietary candidates rather than selling approved products. This creates ongoing execution risk because durable commercial revenue and profitability depend on successful development and eventual regulatory progress.
Assembly Biosciences News
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $19.94 and its highest was $39.70 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $410.47M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 22 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Aug 13, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.724 by $0.524.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.66.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 20,360,596 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.724. Following the earnings report the stock price went up 10.017%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.50 (40.11% Upside)
$49.50 (40.11% Upside)
Blogger Sentiment
Bullish
ASMB Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 376.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 36.5%
Last 30 Days ▲ 36.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.54%
12-Months-Change
Fundamentals
Return on Equity
-0.02%
Trailing 12-Months
Asset Growth
309.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
ASMB Stock 12 Month Forecast
Average Price Target
$49.50
▲(40.11% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
26.40% Insiders
3.69% Mutual Funds
63.30% Other Institutional Investors
1.30% Public Companies and
Individual Investors